// App-Quantinova.ai

22 : EORTC trial 22991: Results of a phase III study comparing 6 months of androgen suppression and irradiation versus irradiation alone for localized T1b-cT2aN0M0 prostate cancer.

Researchers

Presenter

  • Michel Bolla

Principal Investigators

  • Alphonsus C.M. Van Den Bergh

  • Christian Carrie

  • Salvador Vill

  • Petros Kitsios

  • Philip M. Poortmans

  • Santhanam Sundar

  • Elzbieta M. van der Steen-Banasik

  • John Armstrong

  • Jean-Francois Bosset

  • Fernanda Herrera

  • Bradley Pieters

  • Annerie Slot

  • Amit Bahl

  • Laurence Collette

  • Philippe Maingon

Medical Centers

  • Grenoble Alpes University, Centre Hospitalier Universitaire de Grenoble, Grenoble, France

  • University of Groningen, University Medical Center Groningen, Radiotherapy Department, Groningen, Netherlands

  • Leon Berard Center, Radiotherapy Department, Lyon, France

  • Catalan Institute of Oncology - University Hospital Germans Trias i Pujol, Radiation Oncology Department, Badalona, Spain

  • Bank of Cyprus Oncology Centre, Radiotherapy Department, Nicosia, Cyprus

  • Rheumatology Department, University Medical Center Nijmegen, Nijmegen, Netherlands

  • Nottingham University Hospitals NHS Trust - City Hospital, Consultant Medical Oncologist, Nottingham, United Kingdom

  • Arnhem Radiotherapy Institute, Radiotherapy Department, Arnhem, Netherlands

  • ICORG (All Ireland Cooperative Oncology Research Group), St Luke's Hospital, Radiation Oncology Department, Dublin, Ireland

  • University Hospital of Besançon - Jean Minjoz Hospital, Radiotherapy Department, Besançon, France

  • University Hospital of Lausanne, Radiation Oncology Department, Lausanne, Switzerland

  • Academic Medical Center - University of Amsterdam, Radiation Oncology Department, Amsterdam, Netherlands

  • Radiotherapeutisch Instituut Friesland, Leeuwarden, Netherlands

  • University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Department of Oncology, Bristol, United Kingdom

  • EORTC Headquarters, Brussels, Belgium

  • Georges-Francois Leclerc Center, Radiotherapy Department, Dijon, France

Locations

  • France

  • Netherlands

  • Spain

  • Cyprus

  • United Kingdom

  • Ireland

  • Switzerland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT00021450

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved